dimanche 15 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· January 26, 2026

AGNC (AGNC) Q2 2025 Earnings Call Transcript

View original at finance.yahoo.com
AGNC (AGNC) Q2 2025 Earnings Call Transcript Image source: The Motley Fool. Date Tuesday, July 22, 2025 at 8:30 a.m…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Net spread and dollar roll income expected in range of mid- to high $0.30s to low to mid-$0.40s per share

    80% confidence
  • The U.S. government will maintain implicit guarantees for Fannie Mae and Freddie Mac during privatization

    80% confidence
  • The outlook improved in Q2 2025 due to manageable MBS supply, growing MBS demand, stabilizing spreads at cheap levels, and cautious GSE reform approach

    80% confidence
  • Expected MBS net supply for 2025 is approximately $200 billion at the low end of forecasts

    80% confidence
  • GSE privatization must not widen mortgage spreads and should potentially tighten them

    80% confidence
  • GSE reform will follow a do-no-harm approach with no upward pressure on mortgage rates

    80% confidence
  • AGNC has the lowest operating costs in the industry at 111 basis points

    80% confidence
  • Marginal investments are expected to generate high teens returns, somewhere between 18% to 20%

    80% confidence
  • AGNC has no plans to grow for the sake of growing; growth is tied to accretive capital raising

    80% confidence
  • Federal Reserve quantitative tightening expected to end relatively soon, possibly through year-end 2025

    80% confidence
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,997
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,997 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
AGNC (AGNC) Q2 2025 Earnings Call Transcript: Source | Via News | fr.via.news